

Original Research

A comparative study for evaluation of efficacy of 2% mupirocin against topical 2% fusidic acid in treating superficial bacterial infections

¹Ashok Kumar Singh, ²Rohit Garg

¹Associate Professor, Department of Pharmacology, Rama Medical College Hospital & Research Centre, Hapur, Uttar Pradesh, India;

²Associate Professor, Department of Skin & VD, Rama Medical College Hospital & Research Centre, Hapur, Uttar Pradesh, India

ABSTRACT:

Aim: A comparative study for evaluation of efficacy of 2% mupirocin against topical 2% fusidic acid in treating superficial bacterial infections. **Materials and Method:** The present study comprised of 80 patients diagnosed with bacterial infections of the skin. All patients were randomly divided into 2 groups of 40 each. Group I patients were prescribed topical 2% mupirocin and group II were prescribed 2% fusidic acid cream. Grading of the lesions was done with regard to parameters such as erythema, edema, vesiculation, pustulation, crusting, and scaling. Score was applied to each parameter as 0- absent, 1-mild, 2-moderate, and 3-severe. Gram staining was performed. The lesions were graded on first visit (baseline) and subsequent visits on day 4, and day 14. The results were subjected to analysis. P value less than 0.05 was considered significant. **Results:** Group I had 18 males and 22 females and group II had 11 males and 14 females. The mean score at baseline was 8.11±1.54 in group I and 8.88±1.32 in group II, at 4th day was 5.43±0.98 in group I and 5.02±0.89 in group II and at 14th day was 3.03±0.65 in group I and 2.89±0.79 in group II. The difference was non- significant (P>0.05). **Conclusion:** We found that topical 2% mupirocin and topical 2% fusidic acid are well-established in the treatment of uncomplicated bacterial skin infections. Topical mupirocin and topical fusidic acid are equally effective.

Keywords: 2% mupirocin, Topical, 2% fusidic, Bacterial infections

Received: 11 June, 2018

Accepted: 13 July, 2018

Corresponding author: Rohit Garg, Associate Professor, Department of Skin & VD, Rama Medical College Hospital & Research Centre, Hapur, Uttar Pradesh, India

This article may be cited as: Singh AK, Garg R. A comparative study for evaluation of efficacy of 2% mupirocin against topical 2% fusidic acid in treating superficial bacterial infections. J Adv Med Dent Scie Res 2018;6(8):222-224.

INTRODUCTION

It is important to have a good understanding of the common clinical manifestations and pathogens involved in bacterial skin infections to be able to manage them appropriately. The type of skin infection depends on the depth and the skin compartment involved[1]. Bacterial skin infections are the 28th most common diagnosis in hospitalized patients. Cellulitis, impetigo, and folliculitis are the most common bacterial skin infections[2]. Dermatologists are faced with an ever- changing spectrum of bacterial infection in cutaneous diseases. Studies have stated that uncomplicated bacterial skin infections may account for up to 17–25% of clinical visits in India[3]. This high incidence of bacterial infections is due to various precipitating factors such as low socioeconomic status, poor hygiene, malnutrition, overcrowding, and certain immunodeficiency

syndromes. Bacterial skin infections can also complicate other skin diseases such as scabies, varicella, and atopic dermatitis. Majority of the bacterial skin infections are caused by Group A beta-hemolytic *Streptococcus* and *Staphylococcus*[4]. Topical antibacterials are used to accelerate clinical cure, prevent recurrences in affected individuals, and to minimize the spread of infection. They are considered more appropriate as they target only infected area and thus avoid the side effects of the oral treatment and the associated drug interactions. Indiscriminate and universal use of topical medications including antibiotics has led to widespread resistance (molecular, group, and class) to the same[5]. The present study was conducted to compare the efficacy and safety profile of topical 2% mupirocin vs topical 2% fusidic acid in the treatment of superficial bacterial infections.

MATERIALS AND METHODS

The present study comprised of 80 patients diagnosed with bacterial infections of the skin. All patients were informed regarding the study and their consent was obtained. Data such as name, age, gender etc. was recorded. All patients were randomly divided into 2 groups of 40 each. Group I patients were prescribed topical 2% mupirocin and group II were prescribed 2% fusidic acid cream. Grading of the lesions was done with regard to parameters such as erythema, edema, vesiculation, pustulation, crusting, and scaling. Score was applied to each parameter as 0-absent, 1-mild, 2-moderate, and 3-severe. Gram staining was performed. The lesions were graded on first visit (baseline) and subsequent visits on day 4, and day 14. The results were subjected to analysis. P value less than 0.05 was considered significant.

RESULTS

Table 1: Distribution of patients

Groups	Group I	Group II
Drug	Topical 2% mupirocin	Topical 2% Fusidic acid
Gender		
Male	18	16
Female	22	24
Age	37.63±4.64	38.93±5.24

Table 1 shows that group I had 18 males and 22 females and group II had 16 males and 24 females.

Table 2: Comparison of score in both groups

Duration	Group I	Group II	P value
Baseline	8.11±1.54	8.88±1.32	0.18
4 th day	5.43±0.98	5.02±0.89	0.15
14 th day	3.03±0.65	2.89±0.79	0.29

Table 2, shows that mean score at baseline was 8.11±1.54 in group I and 8.88±1.32 in group II, at 4th day was 5.43±0.98 in group I and 5.02±0.89 in group II and at 14th day was 3.03±0.65 in group I and 2.89±0.79 in group II. The difference was non-significant (P>0.05).

DISCUSSION

Impetigo is a superficial bacterial infection that can develop either through direct invasion of normal skin (primary) or infection at sites of damaged skin (secondary). It is common in children and is highly contagious. There are two forms non-bullous or crusted impetigo – distinct yellow, crusting lesions that may be itchy. Typically involves face or extremities. Bullous impetigo is usually caused by *Staphylococcus aureus*. It presents as bullae that rupture to form a brown crust. Boils and carbuncles are associated with infection of a hair follicle and extend into subcutaneous tissue[6]. They are tender and painful but the patient is usually systemically well. In most cases, lesions can be treated with incision and drainage alone. Antibiotic therapy is only required if there is spreading cellulitis or systemic infection. Folliculitis This usually

presents as a crop of pustules affecting areas of moist skin with hair. It is most commonly caused by *S. aureus* but can also be linked to other organisms like *Pseudomonas aeruginosa* when associated with specific exposures like hot tubs and spas[7]. The present study was conducted to compare the efficacy and safety profile of topical 2% mupirocin vs topical 2% fusidic acid in the treatment of superficial bacterial infections. In present study, group I had 18 males and 22 females and group II had 16 males and 24 females. Narayanan V et al[6] compared the efficacy and safety profile of 2% mupirocin versus 2% fusidic acid versus 1% nadifloxacin cream in the treatment of superficial bacterial infections. A total of 90 patients of bacterial infections of the skin were included, which were randomly allocated to three different study groups. Fusidic acid cream showed faster reduction of the scores at the end of the first visit. The differences noted in the efficacy of the three drugs were not statistically significant. No significant side effects were observed. We found that mean score at baseline was 8.11±1.54 in group I and 8.88±1.32 in group II, at 4th day was 5.43±0.98 in group I and 5.02±0.89 in group II and at 14th day was 3.03±0.65 in group I and 2.89±0.79 in group II. The difference was non-significant (P>0.05). Studies recommend that resistance patterns against antibiotics must be taken into consideration in the choice of therapy. Nadifloxacin cream is a newer topical fluoroquinolone antibacterial compound with a benzoquinoline skeleton with fluorine at the sixth position and N-hydroxypiperidine at the eighth position. Fluoroquinolones act by inhibiting the formation of supercoiled DNA by DNA gyrase[9]. It has broad-spectrum activity against Gram-positive bacteria, including coagulase-negative *Staphylococcus* species and *Propionibacterium acnes* granulosum, as has been demonstrated in previous in vitro infections. This agent is also very effective against Gram-negative bacteria including *Pseudomonas aeruginosa* and *Escherichia coli* in in vitro assays[10].

Gilbert et al conducted a study to assess efficacy of Topical 2% mupirocin versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections[11]. He enrolled Thirty-five patients who were treated with mupirocin and 35 patients were treated with fusidic acid three times a day for seven days.

The efficacy of mupirocin, in terms of resolution and improvement of clinical signs and symptoms of infection, as well as of the elimination of infecting organisms, was similar to that of fusidic acid. Of 34 patients (1 could not be evaluated) treated with mupirocin, a clinical cure was achieved in 18, and significant improvement was demonstrated in 15. Similarly, of 35 patients treated with fusidic acid, a clinical cure was achieved in 18 and improvement occurred in 15, Bacteriologic cure rates were 97% (30 of 31 patients evaluated) in the mupirocin-treated

group, compared with 87% (27 of 31 patients evaluated) in the fusidic acid-treated group. No side effects were observed in either treatment group. Author concluded that topical 2% mupirocin has little or no potential for irritation, systemic side effects, or cross-resistance with other antibiotics, its efficacy is likely to make this new compound a useful agent for the treatment of superficial skin infections.

Both cellulitis and erysipelas manifest as spreading areas of skin erythema and warmth. Localised infections are often accompanied by lymphangitis and lymphadenopathy. Not infrequently, groin pain and tenderness due to inguinal lymphadenitis will precede the cellulitis. Some patients can be quite unwell with fevers and features of systemic toxicity. Bacteraemia, although uncommon (less than 5%), still occurs[12] Erysipelas involves the upper dermis and superficial lymphatic skin lesions are usually raised with a clear demarcation of infected skin. Classically, erysipelas affects the face, but it can also involve other areas such as the lower limb. It is most commonly caused by *Streptococcus pyogenes* (group A streptococcus). Cellulitis extends further into the deep dermis and subcutaneous tissue[13]

CONCLUSION

We found that topical 2% mupirocin and topical 2% fusidic acid are well-established in the treatment of uncomplicated bacterial skin infections. Topical mupirocin and topical fusidic acid are equally effective.

REFERENCES

- Alba V, Urban E, Dominguez MA, Nagy E, Nord CE, Palacín C, et al. In vitro activity of nadifloxacin against several Gram-positive bacteria and analysis of the possible evolution of resistance after 2 years of use in Germany. *Intern J antimicrobial agents*. 2009;33(3):272-5.
- Bennett CM, Coombs GW, Wood GM, Howden BP, Johnson LE, White D, et al. Community-onset *Staphylococcus aureus* infections presenting to general practices in South-eastern Australia. *Epidemiol Infect*. 2014;142:501-11.
- Williamson DA, Monecke S, Heffernan H, Ritchie SR, Roberts SA, Upton A et al. High usage of topical fusidic acid and rapid clonal expansion of fusidic acid-resistant *Staphylococcus aureus*: a cautionary tale. *Clin Infect Dis*. 2014;59:1451-4.
- Gottlieb T, Atkins BL, Shaw DR. 7: Soft tissue, bone and joint infections. *Med J Aust*. 2002;176:609-15.
- Thomas KS, Crook AM, Nunn AJ, Foster KA, Mason JM, Chalmers JR et al. U.K. Dermatology Clinical Trials Network's PATCH I Trial Team. Penicillin to prevent recurrent leg cellulitis. *N Engl J Med*. 2013;368:1695-703.
- Narayanan V, Motlekar S, Kadhe G, Bhagat S. Efficacy and safety of nadifloxacin for bacterial skin infections: results from clinical and post-marketing studies. *Dermatol therapy*. 2014;4(2):233-48.
- Mason JM, Thomas KS, Crook AM, Foster KA, Chalmers JR, Nunn AJ et al. Prophylactic antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I & II trials. *PLoS One*. 2014;9:e82694.
- Jacobs MR, Appelbaum PC. Nadifloxacin: A quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. *Expert Opin Pharmacother*. 2006;7:1957-66.
- Choudhury S, Chatterjee S, Sarkar DK, Dutta RN. Efficacy and safety of topical nadifloxacin and benzoyl peroxide versus clindamycin and benzoyl peroxide in acne vulgaris: A randomized controlled trial. *Ind J pharmacol*. 2011;43(6):628.
- Oberai C, Shailendra S, Dalal D, Patil DJ, Patil R, Umrigar D, et al. A comparative clinical study of sisomicin cream versus mupirocin ointment in pyodermas. *Indian J Dermatol Venereol Leprol* 2002;68:78-81.
- Gilbert M. Topical 2% mupirocin versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections. *Journal of the American Academy of Dermatology*. 1989; 20:1083-1087.
- George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. *Br J Gen Pract*. 2003;53:480-7.
- Mehta SM, Garg BR, Kanungo R. A clinico-bacteriological study of primary uncomplicated bacterial skin infections of children in Pondicherry. *Indian J Dermatol Venereol Leprol*. 1992;58:183-7.